Patents by Inventor Martin Conrad Harmsen

Martin Conrad Harmsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomaterial substrates, cell culture systems comprising the same and uses thereof in cell screening applications
    Patent number: 11767505
    Abstract: The invention relates to the fields of biomaterials, tissue engineering and regenerative medicine. More specifically, it relates to biomaterial substrates having precise surface properties and the use thereof to investigate cell-material interactions. Provided is a cell culture system having a biomaterial substrate which has at least a first linear surface gradient oriented orthogonally to a second linear surface gradient, wherein the first gradient and the second gradient are selected from the group consisting of stiffness (S), (aligned) topography (T) and wettability (W). Also provided is a cell screening platform having a combination of at least two, preferably at least three, more preferably four distinct cell culture systems.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 26, 2023
    Assignees: RIJKSUNIVERSITEIT GRONINGEN, ACADEMISCH ZIEKENHUIS GRONINGEN
    Inventors: Patrick van Rijn, Martin Conrad Harmsen, Qihui Zhou, Philipp Till Kuhn, Gabriel Liguori
  • NOVEL BIOMATERIAL SUBSTRATES, CELL CULTURE SYSTEMS COMPRISING THE SAME AND USES THEREOF IN CELL SCREENING APPLICATIONS
    Publication number: 20210130770
    Abstract: The invention relates to the fields of biomaterials, tissue engineering and regenerative medicine. More specifically, it relates to biomaterial substrates having precise surface properties and the use thereof to investigate cell-material interactions. Provided is a cell culture system having a biomaterial substrate which has at least a first linear surface gradient oriented orthogonally to a second linear surface gradient, wherein the first gradient and the second gradient are selected from the group consisting of stiffness (S), (aligned) topography (T) and wettability (W). Also provided is a cell screening platform having a combination of at least two, preferably at least three, more preferably four distinct cell culture systems.
    Type: Application
    Filed: February 23, 2018
    Publication date: May 6, 2021
    Applicants: Rijksuniversiteit Groningen, Academisch Ziekenhuis Groningen
    Inventors: Patrick van Rijn, Martin Conrad Harmsen, Qihui Zhou, Philipp Till Kuhn, Gabriel Liguori
  • BIOCOMPATIBLE COMPOSITIONS FOR TISSUE AUGMENTATION
    Publication number: 20130157956
    Abstract: A crosslinked gelatin hydrogel composition for tissue augmentation.
    Type: Application
    Filed: August 12, 2011
    Publication date: June 20, 2013
    Applicant: FUJIFILM MANUFACTURING EUROPE B.V.
    Inventors: Sebastianus Gerardus Kluijtmans, Annemarie Tuin, Marja Johanna Adriana Van Luyn, Martin Conrad Harmsen, Jan Bastiaan Bouwstra
  • Non-squamous epithelium-specific transcription
    Patent number: 7417137
    Abstract: The invention relates to the field of cancer therapy and diagnosis, in particular of carcinomas. The invention provides an isolated and/or recombinant nucleic acid comprising a tissue specific promoter or functional fragment thereof allowing for expression of a nucleic acid of interest operably linked to said promoter or functional fragment thereof in a cancer cell wherein said expression in said cancer cell is essentially carcinoma selective.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: August 26, 2008
    Assignee: Synvolux IP B.V.
    Inventors: Lou Franciscus M. H. de Leij, Marcel Herman J. Ruiters, Pamela Marijke J. McLaughlin, Martin Conrad Harmsen, Henk van der Molen, Peter Terpstra, Willem Hendrik A. Dokter
  • Non-squamous epithelium-specific transcription
    Publication number: 20020156041
    Abstract: The invention relates to the field of cancer therapy and diagnosis in particular of carcinomas. The invention provides an isolated and/or recombinant nucleic acid comprising a tissue specific promoter or functional fragment thereof allowing for expression of a nucleic acid of interest operably linked to said promoter or functional fragment thereof in a cancer cell wherein said expression in said cancer cell is essentially carcinoma selective.
    Type: Application
    Filed: March 26, 2002
    Publication date: October 24, 2002
    Inventors: Lou Franciscus M. H. De Leij, Marcel Herman J. Ruiters, Pamela Marijke J. McLaughlin, Martin Conrad Harmsen, Henk Van Der Molen, Peter Terpstra, Willem Hendrik A. Dokter